Cells inherently possess biological intelligence, adapting and communicating with precision. Artificial intelligence now replicates this capability, revolutionizing disease diagnosis and treatment through advanced computational models.
Stem-cell therapy, previously reliant on manual processes, is being redefined by AI-native platforms that streamline research, testing, and production. Cellular Intelligence, a Boston-based tech firm led by Israeli entrepreneur Dr. Micha Breakstone, leverages this synergy to address critical global health challenges.
Founded by Breakstone, who previously co-founded Chorus.ai, the company integrates computational modeling with regenerative medicine. Its work is guided by collaborations with experts like Prof. Allon Klein and Dr. Nuno Mendonca, focusing on Parkinson’s and other debilitating conditions.
The company’s platform combines high-throughput data collection with a foundational AI model trained on extensive cellular perturbation datasets. This integration creates a dynamic feedback loop, enhancing predictive capabilities for scalable, consistent cell therapy production.
By decoding cellular signaling patterns, Cellular Intelligence aims to shift biology from observation to predictive engineering.
Following the acquisition of Novo Nordisk’s Parkinson’s cell therapy program, the firm hosted a symposium on AI-biology convergence at Copenhagen’s Novo Nordisk Foundation. The event attracted 28 experts exploring AI’s role in engineering cell fate.
Breakstone emphasized that Parkinson’s, diabetes, epilepsy, and macular degeneration could benefit from their technology. Current Parkinson’s treatments manage symptoms but fail to replace lost neurons, a gap addressed by their STEM-PD approach.
“AI introduces urgency to this field,” Breakstone stated. “While the tools exist, execution remains the challenge.”
A Strategic Ecosystem
Copenhagen’s life sciences heritage makes it an ideal partner. Breakstone notes that AI is being embedded into the region’s therapeutic culture, accelerating progress in complex biological challenges.
Traditional therapies for incurable diseases often take decades and vast resources. AI now enables predictive modeling of cellular responses, significantly shortening development timelines and reducing costs.
“AI accelerates preparation, analysis, and development,” said Jens Nielsen, CEO of BioInnovation Institute. “Cellular Intelligence brings critical technology to biology’s complexity.”
BII supports 130+ startups with €1B+ in funding, highlighting Denmark’s capacity to nurture innovation. Nielsen added that Israel’s biotech strength complements Denmark’s pharma expertise.
Future Potential
Beyond Parkinson’s, Cellular Intelligence explores AI applications for cancer and other diseases. Numerous, co-founded by Vitaly Formin, aims to align drug development with individual biology using its CURE platform, which analyzes clinical trial data to identify biomarkers and optimize trials.
Formin argues that diseases share interconnected patterns. “AI allows us to apply insights across conditions, transforming patient care.”
With interdisciplinary teams of biologists, physicists, and AI experts, such platforms are redefining personalized medicine. Breakstone concludes, “Biology is no longer destiny—it is designed.”